New diabetes device data puts Merck's Januvia on notice

Merck's ($MRK) Januvia has seen its fair share of competition from generics makers and other diabetes challengers. But now, it could face a new rival on the scene--and it's a device. Boston-based Intarcia is touting data showing its tiny, implantable drug pump beat out Merck's best-seller in a head-to-head trial, reducing a type of hemoglobin linked to diabetes twice as much as Januvia. Story

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

Telehealth is surging during the pandemic, however, pharma companies’ place in the booming practice is still emerging.

Merck is expanding its cancer awareness effort with journalist Katie Couric to include survivorship and screening topics and a new podcast next month.